Portal de Periódicos da CAPES

Highlights of the San Antonio Breast Cancer Symposium 2020: Part 2

2021; Future Medicine; Volume: 17; Issue: 21 Linguagem: Inglês

10.2217/fon-2021-0333

1744-8301

John R. Benson, Dorin Dumitru, Ismail Jatoi,

Cancer Genomics and Diagnostics

Future OncologyVol. 17, No. 21 Conference ReportHighlights of the San Antonio Breast Cancer Symposium 2020: part 2John R Benson, Dorin Dumitru & Ismail JatoiJohn R Benson*Author for correspondence: Tel.: +44 122 358 6577; E-mail Address: john.benson@addenbrookes.nhs.ukCambridge Breast Unit, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, UKSchool of Medicine, Anglia Ruskin University, Alan Cherry Dr, Chelmsford, CM1 1SQ, UK, Dorin Dumitru https://orcid.org/0000-0003-4539-0017Breast Unit, Hull University Teaching Hospitals NHS Trust, Castle Road, Cottingham, HU16 5JQ, UKHull York Medical School, Allam Medical Building, University of Hull, Hull, HU6 7RX, UK & Ismail Jatoi https://orcid.org/0000-0002-6775-0039Division of Surgical Oncology, Dale H Dorn Chair in Surgery, University of Texas Health Science Centre, San Antonio, TX 78299, USAPublished Online:1 Jun 2021https://doi.org/10.2217/fon-2021-0333AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: CDK 4/6 inhibitorsdrug conjugatesHER2 positiveImmunotherapymetastaticmultigene assaysSan Antoniotriple-negative breast cancerReferences1. Gao JJ, Cheng J, Bloomquist E et al. CDK4/6 inhibitor treatment for patients with hormone receptor positive, HER2 negative advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 21(2), 250–260 (2020).Crossref, Medline, CAS, Google Scholar2. Mayer EL, Duek AC, Martin M et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label randomized Phase 3 study. Lancet 22(2), 212–222 (2021).Crossref, CAS, Google Scholar3. Schmid P, Cortes J, Pusztai L et al. Pembrolizumab for early triple negative breast cancer. N. Engl. J. Med. 382(9), 810–821 (2020).Crossref, Medline, CAS, Google Scholar4. Gianni L, Huang C-S, Egle D et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high risk and locally advanced breast cancer. NeoTRIP: a PDL1 randomised study. Cancer Res. 80(Suppl. 4), (Abstract GS3–04) (2020).Google Scholar5. Brackley E, Loi S. Targeting immune pathways in breast cancer: review of the prognostic utility of TiLs in early stage triple negative breast cancer (TNBC). Breast 48(Suppl. 1), S44–S48 (2019).Crossref, Medline, Google Scholar6. Mori H, Kubo M, Yamaguchi R et al. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple negative breast cancer. Oncotarget 8(9), 15584–15592 (2017).Crossref, Medline, Google Scholar7. Casey S, Baylot V, Felsher DW. The MYC oncogene is a global regulator of the immune response. Blood 131(18), 2007–2015 (2018).Crossref, Medline, CAS, Google Scholar8. Weinstein IB. Cancer. Addiction to oncogenes – the achilles heal of cancer. Science 297(5578), 63–64 (2002).Crossref, Medline, CAS, Google Scholar9. Sparano JA, Gray RJ, Makower DF et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111–121 (2018).Crossref, Medline, CAS, Google Scholar10. Giuliano A, Ballman K, MacCall L et al. Effect of axillary dissection vs no dissection on 10 year survival amongst women with invasive breast cancer and sentinel metastasis. The ACOSOG Z0011 (Alliance) randomized controlled trial. JAMA 318(10), 918–926 (2017).Crossref, Medline, Google Scholar11. Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 9(48), 28989–29006 (2018).Crossref, Medline, Google Scholar12. Zaman S, Jadid H, Denson AC, Gray JE. Targeting Trop-2 in solid tumors: future prospects. Onco Targets Ther. 12, 1781–1790 (2019).Crossref, Medline, CAS, Google Scholar13. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer 6(3–4), 84–105 (2015).Crossref, Medline, CAS, Google Scholar14. Vidula N, Yau C, Rugo HS. Trop2 gene expression (Trop2e) in primary breast cancer (BC): correlations with clinical and tumor characteristics. J. Clin. Oncol. 35(Suppl. 15), 1075 (2017).Crossref, Google Scholar15. Reference missing.Google Scholar16. Peters C, Brown S. Antibody–drug conjugates as novel anti-cancer chemotherapeutics. Biosci. Rep. 35(4), e00225 (2015).Crossref, Medline, Google Scholar17. Cardillo T, Rossi DL, Zalath MB et al. Predictive biomarkers for sacituzumab govitecan efficacy in TROP-2-expressing triple negative breast cancer. Oncotarget 11, 3849–3862 (2020).Crossref, Medline, Google Scholar18. US FDA. FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer. News release. (2020). www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sacitu-zumab-govitecan-hziy-metastatic-triple-negative-breast-cancerGoogle Scholar19. Modi S, Saura C, Yamashita T et al. Trastuzumab deruxtecan in previously treated HER2 positive breast cancer. N. Engl. J. Med. 382, 610–621 (2020).Crossref, Medline, CAS, Google Scholar20. Okamoto H, Oitate M, Hagugara K et al. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour bearing mice. Xenobiotica 50(10), 1242–1250 (2020).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 17, No. 21 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 73 times History Received 16 March 2020 Accepted 10 May 2020 Published online 1 June 2021 Published in print July 2021 Information© 2021 Future Medicine LtdKeywordsCDK 4/6 inhibitorsdrug conjugatesHER2 positiveImmunotherapymetastaticmultigene assaysSan Antoniotriple-negative breast cancerFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download